Company Announcements

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of EGM

Cambridge, UK, 28 February 2022 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, held its Extraordinary General Meeting ("EGM") today and all resolutions were duly passed. Details of the proxy voting are shown in the table below. 

ISC - Issued Share Capital

Share Consolidation

Following the approval of Resolution 2, every 50 ordinary shares of 0.00025 pence each (the "Existing Shares") that are in issue as at 6.00 p.m. today will be consolidated into one new ordinary share of 0.0125 pence each (the "New Ordinary Shares"). Other than the change in nominal value, the New Ordinary Shares arising on implementation of the share consolidation will have the same rights as the Existing Ordinary Shares, including voting and other rights.

It is expected that the New Ordinary Shares arising from the share consolidation will be admitted to trading AIM from 8.00 a.m. on 1 March 2022 ("Admission") with ISIN number GB00BMC3RJ87.

Immediately following Admission, the Company will have 68,069,416 ordinary shares of 0.0125 pence each in issue; therefore the total voting rights in the Company will be 68,069,416. This figure may be used by shareholders in the Company as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The full text of each of the resolutions is set out in the Notice of EGM, available in the Investors section of the Company's website (www.sareum.com/investors).

For further information, please contact:

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com 

- Ends -